Posts
World Pharma News |  |
| Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain Posted: 12 Nov 2009 03:00 PM PST Abbott (NYSE: ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.
|
| You are subscribed to email updates from World Pharma News To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |